The advent of novel systemic therapies has significantly enhanced survival outcomes in patients with metastatic breast cancer. Treatment selection is guided by tumor biology, specifically hormone-receptor and HER2 status, alongside clinical factors, thereby facilitating personalized therapeutic strategies and improved patient prognosis as of 2020.